Published in Expert Opin Investig Drugs on March 01, 2008
Three decades of beta-lactamase inhibitors. Clin Microbiol Rev (2010) 5.54
Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae. Antimicrob Agents Chemother (2010) 2.54
Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor. Antimicrob Agents Chemother (2010) 1.87
In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob Agents Chemother (2009) 1.80
Priming innate immune responses to infection by cyclooxygenase inhibition kills antibiotic-susceptible and -resistant bacteria. Blood (2010) 1.73
Antibiotics and bacterial resistance in the 21st century. Perspect Medicin Chem (2014) 1.41
Newer antibacterial drugs for a new century. Expert Opin Investig Drugs (2010) 1.16
In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013. Antimicrob Agents Chemother (2015) 0.99
New treatment options against gram-negative organisms. Crit Care (2011) 0.98
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. Antimicrob Agents Chemother (2008) 0.85
Inhibition of class A and C beta-lactamases by diaroyl phosphates. Biochemistry (2009) 0.84
Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. Antimicrob Agents Chemother (2009) 0.80
Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother (2017) 0.75
Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis (2012) 4.62
Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis (2013) 4.06
A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. Intensive Care Med (2014) 3.56
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A (2012) 2.50
Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis (2006) 1.89
HIV-1 envelope protein gp120 is present at high concentrations in secondary lymphoid organs of individuals with chronic HIV-1 infection. J Infect Dis (2009) 1.82
A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med (2013) 1.74
Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One (2011) 1.73
A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis (2007) 1.68
Bloodstream infections and invasive mycoses in children undergoing acute leukaemia treatment: a 13-year experience at a single Italian institution. Eur J Cancer (2005) 1.66
A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Med (2015) 1.54
Drug treatment for multidrug-resistant Acinetobacter baumannii infections. Future Microbiol (2008) 1.38
European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica (2013) 1.26
Fungal infections in children with cancer: a prospective, multicenter surveillance study. Pediatr Infect Dis J (2006) 1.25
Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance. Biol Blood Marrow Transplant (2009) 1.25
Candida infective endocarditis: report of 15 cases from a prospective multicenter study. Medicine (Baltimore) (2009) 1.24
Ocular manifestations of candidemia. Clin Infect Dis (2011) 1.22
A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther (2003) 1.19
A case of secondary syphilis presenting as optic neuritis. Neurol Sci (2010) 1.17
Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagn Microbiol Infect Dis (2007) 1.17
The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care (2010) 1.17
Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain. J Clin Microbiol (2013) 1.10
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. New Microbiol (2012) 1.10
(1-3)-β-D-glucan in cerebrospinal fluid is useful for the diagnosis of central nervous system fungal infections. Clin Infect Dis (2013) 1.09
Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation. Haematologica (2004) 1.08
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. New Microbiol (2010) 1.06
Latent tuberculosis infection and associated risk factors among undergraduate healthcare students in Italy: a cross-sectional study. BMC Infect Dis (2013) 1.06
Correlation of CXCL12 expression and FoxP3+ cell infiltration with human papillomavirus infection and clinicopathological progression of cervical cancer. Am J Pathol (2009) 1.06
High Levels of beta-D-glucan in immunocompromised children with proven invasive fungal disease. Clin Vaccine Immunol (2010) 1.05
Clinical evaluation of a (1,3)-beta-D-glucan assay for presumptive diagnosis of Pneumocystis jiroveci pneumonia in immunocompromised patients. Clin Vaccine Immunol (2009) 1.03
Tigecycline use in serious nosocomial infections: a drug use evaluation. BMC Infect Dis (2010) 1.02
Aspergillus meningitis: a rare clinical manifestation of central nervous system aspergillosis. Case report and review of 92 cases. J Infect (2012) 1.02
Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Clin Infect Dis (2009) 1.02
Evaluation of insulin resistance in a cohort of HIV-infected youth. Eur J Endocrinol (2007) 1.01
Clinical performance of the (1,3)-β-D-glucan assay in early diagnosis of nosocomial Candida bloodstream infections. Clin Vaccine Immunol (2011) 1.00
Linezolid in the treatment of Gram-positive prosthetic joint infections. J Antimicrob Chemother (2005) 1.00
Incidence of candidaemia and relationship with fluconazole use in an intensive care unit. J Antimicrob Chemother (2009) 1.00
Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). Haematologica (2013) 0.99
High-dose daptomycin in documented Staphylococcus aureus infections. Int J Antimicrob Agents (2010) 0.98
Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. Clinicoecon Outcomes Res (2011) 0.97
A multicenter, randomized, double blind placebo-controlled trial of amoxicillin/clavulanate for the prophylaxis of fever and infection in neutropenic children with cancer. Pediatr Infect Dis J (2003) 0.96
Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis (2003) 0.96
Voriconazole in clinical practice. J Chemother (2012) 0.96
Galactomannan testing might be useful for early diagnosis of fusariosis. Diagn Microbiol Infect Dis (2012) 0.96
Occurrence, presentation and treatment of candidemia. Expert Rev Clin Immunol (2012) 0.96
Combination therapy for invasive aspergillosis. Clin Infect Dis (2004) 0.95
Current status of newer carbapenems. Curr Med Chem (2009) 0.95
Screening with serum galactomannan might be associated with better outcome than symptom-triggered galactomannan testing in allogeneic HSCT recipients with invasive aspergillosis. Clin Infect Dis (2013) 0.95
Conditions associated with infections of indwelling central venous catheters in cancer patients: a summary. Br J Haematol (2003) 0.95
Multidrug-resistant bacteria: what is the threat? Hematology Am Soc Hematol Educ Program (2013) 0.93
The use of nucleoside reverse transcriptase inhibitors sparing regimens in treatment-experienced HIV-1 infected patients. Curr HIV Res (2013) 0.90
Bench-to-bedside review: therapeutic management of invasive candidiasis in the intensive care unit. Crit Care (2010) 0.90
Epidemiology and risk factors for bloodstream infections after allogeneic hematopoietic stem cell transplantion. New Microbiol (2007) 0.90
Galactomannan in piperacillin-tazobactam: how much and to what extent? Antimicrob Agents Chemother (2005) 0.89
How to manage aspergillosis in non-neutropenic intensive care unit patients. Crit Care (2014) 0.89
Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration. J Antimicrob Chemother (2006) 0.88
Effectiveness of a project to prevent HIV vertical transmission in the Republic of Congo. J Antimicrob Chemother (2013) 0.88
Pseudomonas aeruginosa serious infections: mono or combination antimicrobial therapy? Curr Med Chem (2008) 0.88
A European Organization for Research and Treatment of Cancer-International Antimicrobial Therapy Group Study of secondary infections in febrile, neutropenic patients with cancer. Clin Infect Dis (2004) 0.88
Long course of daptomycin in the treatment of meticillin-resistant Staphylococcus epidermidis endocarditis and spondylodiscitis. Int J Antimicrob Agents (2009) 0.87
X4 human immunodeficiency virus type 1 gp120 down-modulates expression and immunogenicity of codelivered antigens. J Virol (2009) 0.87
Patient-reported outcomes and low-level residual HIV-RNA in adolescents perinatally infected with HIV-1 after switching to one-pill fixed-dose regimen. AIDS Care (2011) 0.86
Delafloxacin for the treatment of respiratory and skin infections. Expert Opin Investig Drugs (2015) 0.86
Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens. Future Microbiol (2014) 0.85
Bordetella holmesii endocarditis in a patient with systemic lupus erythematous treated with immunosuppressive agents. J Chemother (2012) 0.84
Seroprevalence and vaccination coverage of vaccine-preventable diseases in perinatally HIV-1-infected patients. Hum Vaccin Immunother (2014) 0.84
Invasive aspergillosis: diagnosis, prophylaxis and treatment. Curr Opin Hematol (2008) 0.84
Development of novel antibacterial drugs to combat multiple resistant organisms. Langenbecks Arch Surg (2015) 0.84
Identification of a New Delhi metallo-β-lactamase-4 (NDM-4)-producing Escherichia coli in Italy. BMC Microbiol (2014) 0.84
Adherence to international and national recommendations for the prevention of surgical site infections in Italy: results from an observational prospective study in elective surgery. Am J Infect Control (2012) 0.83
Bacterial infections in hematopoietic stem cell transplantation recipients. Curr Opin Hematol (2014) 0.83
Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin. Br J Haematol (2006) 0.83
A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma. J Hematol Oncol (2014) 0.83
Invasive candidiasis in non-hematological patients. Mediterr J Hematol Infect Dis (2011) 0.83
Use of raltegravir in a late presenter HIV-1 woman in advanced gestational age: case report and literature review. J Chemother (2013) 0.82
Measles outbreak in adults in Italy. Infez Med (2011) 0.82
Transitioning HIV-infected children and adolescents into adult care: an Italian real-life experience. J Assoc Nurses AIDS Care (2015) 0.81
New antibiotics and antimicrobial combination therapy for the treatment of gram-negative bacterial infections. Curr Opin Crit Care (2015) 0.81
Managing invasive fungal infections: relying on clinical instincts or on a rational navigation system? J Antimicrob Chemother (2011) 0.81
Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient. J Antimicrob Chemother (2009) 0.81
Whole body bone scintigraphy in tenofovir-related osteomalacia: a case report. J Med Case Rep (2009) 0.81
Caspofungin use in daily clinical practice for treatment of invasive aspergillosis: results of a prospective observational registry. BMC Infect Dis (2010) 0.81
Current role of echinocandins in the management of invasive aspergillosis. Curr Infect Dis Rep (2011) 0.80
Risk associated with a systematic search of extended-spectrum β-lactamase-producing Enterobacteriaceae. Am J Infect Control (2012) 0.80
HIV serological screening in a population of pregnant women in the Republic of Congo: suitability of different assays. Trop Med Int Health (2008) 0.80
Candida infections in the intensive care unit: epidemiology, risk factors and therapeutic strategies. Expert Rev Anti Infect Ther (2006) 0.80
CMV infection after transplant from cord blood compared to other alternative donors: the importance of donor-negative CMV serostatus. Biol Blood Marrow Transplant (2011) 0.80
Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum beta-lactamase-producing organisms in an intensive care unit. J Antimicrob Chemother (2007) 0.80